<DOC>
	<DOC>NCT01118962</DOC>
	<brief_summary>The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy. Additionally, to allow subjects who have completed SP0961 (NCT01118949) to continue to receive Lacosamide.</brief_summary>
	<brief_title>Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy, Generalized</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject completed the SP0961 (NCT01118949) study Subject is expected to benefit from participation in an openlabel extension study with Lacosamide, in the opinion of the investigator Subject meets the withdrawal criteria for SP0961 (NCT01118949) or is experiencing an ongoing Serious Adverse Event (SAE)</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Primary Generalized Tonic-Clonic (PGTC) Seizures</keyword>
	<keyword>Absence Seizures</keyword>
	<keyword>Myoclonic Seizures</keyword>
	<keyword>Idiopathic Generalized Epilepsy (IGE)</keyword>
</DOC>